Research programme: VHH single domain antibodies - Primrose Bio
Alternative Names: PF-901Latest Information Update: 28 Sep 2024
At a glance
- Originator Pfenex
- Developer Primrose Bio
- Class Single-domain antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Haematological disorders
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Haematological-disorders in USA (Parenteral)
- 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
- 01 Oct 2020 Pfenex has been acquired by Ligand Pharmaceuticals